Ticker Scorecard - FDMT Basics Company: 4D Molecular Therapeutics, Inc. IPO Date: December 11, 2020 Sector: Healthcare Industry: Biotech Market Cap: $214.5M Activated in VL: True Average Daily Range Avg Daily Range: $0.69 | 3.48% Avg Daily Range (30 D): $0.24 | 4.42% Avg Daily Range (90 D): $0.24 | 3.61% Institutional Daily Volume Avg Daily Volume: .37M Avg Daily Volume (30 D): .75M Avg Daily Volume (90 D): .71M Trade Size Avg Trade Size (Sh.): 71 Avg Trade Size (Sh.) (30 D): 94 Avg Trade Size (Sh.) (90 D): 83 Institutional Trades Total Inst.Trades: 1,036 Avg Inst. Trade: $1.86M Avg Inst. Trade (30 D): $1.42M Avg Inst. Trade (90 D): $1.53M Avg Inst. Trade Volume: .11M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.87M Avg Closing Trade (30 D): $.82M Avg Closing Trade (90 D): $1.09M Avg Closing Volume: 98.42K     News Feb 21, 2025 @ 6:00 PM Cell and Gene Therapies in Rare Disorders Market t... Source: Delveinsight Feb 19, 2025 @ 1:00 PM 4DMT to Participate in Upcoming Investor Conferenc... Source: 4D Molecular Therapeutics Feb 8, 2025 @ 7:30 PM 4DMT Presents Positive 52-Week Results from Phase ... Source: 4D Molecular Therapeutics Sep 12, 2024 @ 9:49 PM FDMT Investors Have Opportunity to Join 4D Molecul... Source: Business Wire Sep 3, 2024 @ 12:00 PM 4DMT to Participate in the 2024 Cantor Global Heal... Source: N/A Financials   TTM Q3 2024 Q2 2024 Basic EPS $-2.85 $-.79 $-.63 Diluted EPS $-2.85 $-.79 $-.63 Revenue $ .02M $ M $ .01M Gross Profit $ $ $ Net Income / Loss $ -143.48M $ -43.84M $ -34.95M Operating Income / Loss $ -168.38M $ -51.13M $ -42.46M Cost of Revenue $ $ $ Net Cash Flow $ -88.14M $ -1.52M $ -86.53M PE Ratio